Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 542

The DOI matches its Crossref record.

In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase

Open access
Garcı́a-Echeverrı́a, Carlos, Pearson, Mark A, Marti, Andreas, Meyer, Thomas, Mestan, Juergen, Zimmermann, Johann, Gao, Jiaping, Brueggen, Josef, Capraro, Hans-Georg, Cozens, Robert, Evans, Dean B, Fabbro, Doriano, Furet, Pascal, Porta, Diana Graus, Liebetanz, Janis, Martiny-Baron, Georg, Ruetz, Stephan, Hofmann, Francesco·2004·Cancer Cell
DOI 10.1016/s1535-6108(04)00051-0
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(04)00051-0

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 52

  1. Alessi, 1996, Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase, FEBS Lett., 399, 333, 10.1016/S0014-5793(96)01370-1 · DOI · Paper page
  2. Arion, 1988, Cdc 2 is a component of the M-phase specific histone H1 kinase, Cell, 55, 371, 10.1016/0092-8674(88)90060-8 · DOI · Paper page
  3. Artega, 1989, Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor, Cancer Res., 49, 6237
  4. Azzi, 1992, Interaction between the cell cycle control protein p34cdc2 and p9CKShs, Eur. J. Biochem., 203, 353, 10.1111/j.1432-1033.1992.tb16557.x · doi:10.1111/j.1432-1033.1992.tb16557.x
  5. Baserga, 2000, The contradictions of the insulin-like growth factor 1 receptor, Oncogene, 19, 5574, 10.1038/sj.onc.1203854 · DOI · Paper page
  6. Bazzoni, 1996, Bcr/Abl expression stimulates integrin function in hematopoietic cell lines, J. Clin. Invest., 98, 521, 10.1172/JCI118820 · DOI
  7. Bhat, 1997, Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells, J. Biol. Chem., 272, 16170, 10.1074/jbc.272.26.16170 · DOI
  8. Burfeind, 1996, Antisense RNA to the type I insulin-like growth factor receptor suppresses tumour growth and prevents invasion by rat prostate cancer cells in vivo, Proc. Natl. Acad. Sci. USA, 93, 7263, 10.1073/pnas.93.14.7263 · DOI · Paper page
  9. Chernicky, 2000, Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumourogenesis, alters the metastatic potential and prolongs survival in vivo, Cancer Gene Ther., 7, 384, 10.1038/sj.cgt.7700126 · doi:10.1038/sj.cgt.7700126
  10. Coppola, 1994, A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor, Mol. Cell. Biol., 14, 4588, 10.1128/MCB.14.7.4588 · DOI · Paper page
  11. D'Ambrosio, 1996, A soluble Insulin-like growth factor I receptor that induces apoptosis of tumour cells in vivo and inhibits tumourogenesis, Cancer Res., 56, 4013
  12. De Angelis, 1995, R. Insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the platelet-derived growth factor receptor, J. Cell. Physiol., 164, 214, 10.1002/jcp.1041640126 · doi:10.1002/jcp.1041640126
  13. De Leon, 1992, Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies on the proliferation of human breast cancer cells, Growth Factors, 6, 327, 10.3109/08977199209021544 · doi:10.3109/08977199209021544
  14. Dunn, 1998, A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion and metastasis of breast cancer, Cancer Res., 58, 3353
  15. Freedman, 1974, Cellular tumourigenicity in nude mice, Cell, 3, 355, 10.1016/0092-8674(74)90050-6 · DOI · Paper page
  16. Fürstenberger, 2002, Insulin-like growth factors and cancer, Lancet Oncol., 3, 298, 10.1016/S1470-2045(02)00731-3 · DOI · Paper page
  17. Geiges, 1997, Activation of PKC subtypes α,γ,δ,ϵ,ζ and η by tumour promoting and non-tumour promoting agents, Biochem. Pharmacol., 53, 865, 10.1016/S0006-2952(96)00885-4 · DOI
  18. Grimberg, 2000, Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis, J. Cell. Physiol., 183, 1, 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J · DOI · Paper page
  19. Kalebic, 1998, Expression of a kinase deficient IGF-IR suppresses tumourogenicity of rhabdomyosarcoma cells constitutively expressing a wild-type IGF-IR, Int. J. Cancer, 76, 223, 10.1002/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z · doi:10.1002/(sici)1097-0215(19980413)76:2<223::aid-ijc9>3.0.co;2-z
  20. Kaleko, 1990, Overexpression of the human insulin-like growth factor I receptor promotes ligand dependent neoplastic transformation, Mol. Cell. Biol., 10, 464, 10.1128/MCB.10.2.464 · DOI · Paper page
  21. Kato, 1993, Role of tyrosine kinase activity in signal transduction by the insulin-like growth factors (IGF-I) receptor, J. Biol. Chem., 268, 2655, 10.1016/S0021-9258(18)53824-2 · DOI · Paper page
  22. Khandwala, 2000, The effects of insulin-like growth factors on tumourogenesis and neoplastic growth, Endocr. Rev., 21, 215, 10.1210/edrv.21.3.0399 · DOI · Paper page
  23. Li, 2000, Activation of insulin-like growth factor I receptor signaling pathway is critical for mouse plasma cell tumour growth, Cancer Res., 60, 3909
  24. Long, 1995, Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to insulin-like growth factor receptor, Cancer Res., 55, 1006
  25. Lopez, 2002, Elevated levels of the IGF-I receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumourogenesis, Cancer Cell, 1, 339, 10.1016/S1535-6108(02)00055-7 · DOI · Paper page
  26. McGlynn, 1992, Large scale purification and characterization of a recombinant epidermal growth factor receptor protein tyrosine kinase, Eur. J. Biochem., 207, 265, 10.1111/j.1432-1033.1992.tb17047.x · DOI
  27. Mitsiades, 2004, Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors, Cancer Cell, 5, 221, 10.1016/S1535-6108(04)00050-9 · DOI · Paper page
  28. Meijer, 1989, Cyclin is a component of the sea urchin egg M-Phase specific histone H1 kinase, EMBO J., 8, 2275, 10.1002/j.1460-2075.1989.tb08353.x · DOI · Paper page
  29. Meijer, 1991, Cyclin B targets p34cdc2 for tyrosine phosphorylation, EMBO J., 8, 2275, 10.1002/j.1460-2075.1989.tb08353.x · DOI · Paper page
  30. Nakamura, 2000, Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines, Cancer Res., 60, 760
  31. Prager, 1994, Dominant negative inhibition of tumourogenesis in vivo by human insulin-like growth factor I receptor mutant, Proc. Natl. Acad. Sci. USA, 91, 2181, 10.1073/pnas.91.6.2181 · doi:10.1073/pnas.91.6.2181
  32. Pronk, 1994, Involvement of Shc in Insulin- and Epidermal Growth Factor-induced activation of p21ras, Mol. Cell. Biol., 14, 1575, 10.1128/MCB.14.3.1575 · DOI
  33. Resnicoff, 1994, Growth inhibition of human melanoma cells in nude mice by antisense strategies to type 1 insulin-like growth factor receptor, Cancer Res., 54, 4848
  34. Resnicoff, 1995, Correlation between apoptosis, tumourogenesis and the levels of insulin-like growth factor I receptor, Cancer Res., 55, 3739
  35. Reiss, 1998, Inhibition of tumour growth by a dominant negative mutant of the insulin-like growth factor I receptor with a bystander effect, Clin. Cancer Res., 4, 2647
  36. Rialet, 1991, A new screening test for antimitotic compounds using universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates, Anticancer Res., 11, 1581
  37. Samani, 2001, Inhibition of carcinoma cell growth and metastasis by a vesicular stomatitis virus G-pseudotyped retrovector expressing type I insulin-like growth factor receptor antisense, Hum. Gene Ther., 12, 1969, 10.1089/104303401753204544 · doi:10.1089/104303401753204544
  38. Scotlandi, 1998, Blockage of insulin-like growth factor I receptor inhibits the growth of Ewing's sarcoma in athymic mice, Cancer Res., 58, 4127
  39. Scotlandi, 2002, Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumourogenesis and enhances chemosensitivity in Ewing's sarcoma cells, Int. J. Cancer, 101, 11, 10.1002/ijc.10537 · DOI
  40. Scotlandi, 2002, Effectiveness of insulin-like growth factor I receptor antisense strategy againstEwing's sarcoma cells, Cancer Gene Ther., 9, 296, 10.1038/sj.cgt.7700442 · DOI
  41. Sell, 1993, Simian virus 40 large tumour antigen is unable to transform mouse embryonic fibroblasts lacking type I Insulin-like growth factor receptor, Proc. Natl. Acad. Sci. USA, 90, 11217, 10.1073/pnas.90.23.11217 · DOI · Paper page
  42. Sell, 1994, Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts, Mol. Cell. Biol., 14, 3604, 10.1128/MCB.14.6.3604 · DOI · Paper page
  43. Shapiro, 1994, Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma, J. Clin. Invest., 94, 1235, 10.1172/JCI117441 · doi:10.1172/jci117441
  44. Stabel, 1991, Expression of protein kinase C isotypes in baculovirus vectors, Methods Enzymol., 200, 670, 10.1016/0076-6879(91)00179-Z · doi:10.1016/0076-6879(91)00179-z
  45. Stiles, 1979, Dual control of cell growth by somatomedins and platelet-derived growth factor, Proc. Natl. Acad. Sci. USA, 76, 1279, 10.1073/pnas.76.3.1279 · DOI · Paper page
  46. Ullrich, 1990, Signal transduction by receptors tyrosine kinase activity, Cell, 61, 203, 10.1016/0092-8674(90)90801-K · DOI · Paper page
  47. Valentinis, 1997, Insulin-like growth factor I receptor signaling in transformation by Src oncogenes, Mol. Cell. Biol., 17, 3744, 10.1128/MCB.17.7.3744 · DOI
  48. Van der Geer, 1994, Receptor protein-tyrosine kinases and their signal transduction pathways, Annu. Rev. Cell Biol., 10, 251, 10.1146/annurev.cellbio.10.1.251 · DOI
  49. Wang, 2002, Insulin-like growth factor receptor-1 as an anti-cancer target, Curr. Cancer Drug Targets, 2, 191, 10.2174/1568009023333863 · DOI
  50. White, 2000, Antisense inhibition of IGF-I receptor expression in HaCaT keratinocytes, Antisense Nucleic Acid Drug Dev., 10, 195, 10.1089/oli.1.2000.10.195 · doi:10.1089/oli.1.2000.10.195
  51. Williams, 1992, Both p21ras and pp60v-src are required, but neither alone is sufficient, to activate the Raf-1 kinase, Proc. Natl. Acad. Sci. USA, 89, 2922, 10.1073/pnas.89.7.2922 · DOI
  52. Yu, 2000, Role of the insulin-like growth factor family in cancer development and progression, J. Natl. Cancer Inst., 92, 1472, 10.1093/jnci/92.18.1472 · DOI · Paper page

Cited by

See all 542

Metadata

Authors
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., Evans, D. B., Fabbro, D., Furet, P., Porta, D. G., Liebetanz, J., Martiny-Baron, G., Ruetz, S., & Hofmann, F.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2004-03
Volume
5
Issue
3
Pages
231-239
ISSN
1535-6108 (ISSN-L)
DOI
10.1016/s1535-6108(04)00051-0
OpenAlex
W1999030960
Cited by
542
References
0
FWCI
28.62
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. https://app.cochat.ai/papers/10.1016/s1535-6108(04)00051-0
The paper
Garcı́a-Echeverrı́a, C., Pearson, M. A., Marti, A., Meyer, T., Mestan, J., Zimmermann, J., Gao, J., Brueggen, J., Capraro, H.-G., Cozens, R., Evans, D. B., Fabbro, D., Furet, P., Porta, D. G., Liebetanz, J., Martiny-Baron, G., Ruetz, S., & Hofmann, F. (2004). In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. https://doi.org/10.1016/s1535-6108(04)00051-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.